299 related articles for article (PubMed ID: 32152062)
1. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).
Starzer AM; Berghoff AS
ESMO Open; 2020 Mar; 4(Suppl 3):e000629. PubMed ID: 32152062
[TBL] [Abstract][Full Text] [Related]
2. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
Wasiuk A; Weidlick J; Sisson C; Widger J; Crocker A; Vitale L; Marsh HC; Keler T; He LZ
Cancer Immunol Immunother; 2022 Jan; 71(1):97-109. PubMed ID: 34028568
[TBL] [Abstract][Full Text] [Related]
3. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.
Buchan SL; Rogel A; Al-Shamkhani A
Blood; 2018 Jan; 131(1):39-48. PubMed ID: 29118006
[TBL] [Abstract][Full Text] [Related]
4. CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization.
Taraban VY; Rowley TF; Kerr JP; Willoughby JE; Johnson PM; Al-Shamkhani A; Buchan SL
Eur J Immunol; 2013 Dec; 43(12):3314-23. PubMed ID: 24002868
[TBL] [Abstract][Full Text] [Related]
5. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
[No Abstract] [Full Text] [Related]
7. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
8. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
van de Ven K; Borst J
Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
[TBL] [Abstract][Full Text] [Related]
9. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
Silence K; Dreier T; Moshir M; Ulrichts P; Gabriels SM; Saunders M; Wajant H; Brouckaert P; Huyghe L; Van Hauwermeiren T; Thibault A; De Haard HJ
MAbs; 2014; 6(2):523-32. PubMed ID: 24492296
[TBL] [Abstract][Full Text] [Related]
10. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
11. Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.
Bullock TN
Curr Opin Immunol; 2017 Apr; 45():82-88. PubMed ID: 28319731
[TBL] [Abstract][Full Text] [Related]
12. Frontline Science: Late CD27 stimulation promotes IL-7Rα transcriptional re-expression and memory T cell qualities in effector CD8
Dong H; Buckner A; Prince J; Bullock T
J Leukoc Biol; 2019 Nov; 106(5):1007-1019. PubMed ID: 31199542
[TBL] [Abstract][Full Text] [Related]
13. Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex.
Liu W; Maben Z; Wang C; Lindquist KC; Li M; Rayannavar V; Lopez Armenta I; Nager A; Pascua E; Dominik PK; Oyen D; Wang H; Roach RC; Allan CM; Mosyak L; Chaparro-Riggers J
J Biol Chem; 2021 Oct; 297(4):101102. PubMed ID: 34419446
[TBL] [Abstract][Full Text] [Related]
14. CD70 expression in tumor-associated fibroblasts predicts worse survival in colorectal cancer patients.
Inoue S; Ito H; Tsunoda T; Murakami H; Ebi M; Ogasawara N; Kasugai K; Kasai K; Ikeda H; Inaguma S
Virchows Arch; 2019 Oct; 475(4):425-434. PubMed ID: 30980190
[TBL] [Abstract][Full Text] [Related]
15. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
Mizuno R; Maruhashi T; Sugiura D; Shimizu K; Watada M; Okazaki IM; Okazaki T
Biochem Biophys Res Commun; 2019 Apr; 511(3):491-497. PubMed ID: 30771904
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer.
Kong F; Ye Q; Xiong Y
Funct Integr Genomics; 2023 Jan; 23(1):48. PubMed ID: 36700974
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity.
Orengo AM; Cantoni C; Neglia F; Biassoni R; Ferrini S
Clin Exp Immunol; 1997 Mar; 107(3):608-13. PubMed ID: 9067541
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab.
Ramakrishna V; Sundarapandiyan K; Zhao B; Bylesjo M; Marsh HC; Keler T
J Immunother Cancer; 2015; 3():37. PubMed ID: 26500773
[TBL] [Abstract][Full Text] [Related]
19. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Huang J; Kerstann KW; Ahmadzadeh M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunol; 2006 Jun; 176(12):7726-35. PubMed ID: 16751420
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L; Fischmann TO; Wong J; Mauze S; Guadagnoli M; Bąbała N; Wagenaars J; Juan V; Rosen D; Prosise W; Habraken M; Lodewijks I; Gu D; Stammen-Vogelzangs J; Yu Y; Baker J; Lutje Hulsik D; Driessen-Engels L; Malashock D; Kreijtz J; Bertens A; de Vries E; Bovens A; Bramer A; Zhang Y; Wnek R; Troth S; Chartash E; Dobrenkov K; Sadekova S; van Elsas A; Cheung JK; Fayadat-Dilman L; Borst J; Beebe AM; Van Eenennaam H
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
